PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
NASDAQ:PYPD
Price:
4.94 USD
2.92%
Market Closed
Updated:
May 6, 2024
PolyPid Ltd
Cash from Financing Activities
|
PolyPid Ltd
Cash from Financing Activities Peer Comparison
Comparables:
T
TEVA
TARO
I
INCR
MDWD
R
REKA
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Cash from Financing Activities
$10m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cash from Financing Activities
-$1.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Cash from Financing Activities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
I
|
InterCure Ltd
TASE:INCR
|
Cash from Financing Activities
₪42.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
82%
|
CAGR 10-Years
26%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Cash from Financing Activities
$22.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
241%
|
CAGR 10-Years
2%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cash from Financing Activities
-₪10.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is PolyPid Ltd's Cash from Financing Activities?
Cash from Financing Activities
10m
USD
10m
USD
Based on the financial report for Dec 31, 2023, PolyPid Ltd's Cash from Financing Activities amounts to 10m USD.
What is PolyPid Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
1%
1%
Over the last year, the Cash from Financing Activities growth was -39%. The average annual Cash from Financing Activities growth rates for PolyPid Ltd have been -46% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
